Tormod S Nilsen1, Jessica M Scott2,3, Meghan Michalski2, Catherine Capaci2, Samantha Thomas4, James E Herndon4, John Sasso5, Neil D Eves5, Lee W Jones2,3. 1. Department of Physical Performance, The Norwegian School of Sport Sciences, Oslo, NORWAY. 2. Memorial Sloan Kettering Cancer Center, New York, NY. 3. Weill Cornell Medical College, New York, NY. 4. Duke University Medical Center, Durham, NC. 5. Centre for Heart, Lung and Vascular Health, School of Health and Exercise Sciences, University of British Columbia Okanagan, Kelowna, British Columbia, CANADA.
Abstract
PURPOSE: The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. METHODS: Using a retrospective analysis of a randomized trial, 25 prostate cancer patients received an aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly between 55% and 100% of exercise capacity for 24 consecutive weeks. Treatment adherence (tolerability) was assessed using conventional (lost to follow-up and attendance) and exploratory (e.g., permanent discontinuation, dose modification, and relative dose intensity) outcomes. RESULTS: The mean total cumulative "planned" and "completed" dose was 200.7 ± 47.6 and 153.8 ± 68.8 MET·h, respectively, equating to a mean relative dose intensity of 77% ± 24%. Two patients (8%) were lost to follow-up, and mean attendance was 79%. A total of 6 (24%) of 25 patients permanently discontinued aerobic training before week 24. Aerobic training was interrupted (missing ≥3 consecutive sessions) or dose reduced in a total of 11 (44%) and 24 (96%) patients, respectively; a total 185 (10%) of 1800 training sessions required dose reduction owing to both health-related (all nonserious) and non-health-related adverse events. Eighteen (72%) patients required at least one session to be terminated early; a total of 59 (3%) sessions required early termination. CONCLUSIONS: Novel methods for the conduct and reporting of exercise treatment adherence and tolerability may provide important information beyond conventional metrics in patients with cancer.
RCT Entities:
PURPOSE: The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. METHODS: Using a retrospective analysis of a randomized trial, 25 prostate cancerpatients received an aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly between 55% and 100% of exercise capacity for 24 consecutive weeks. Treatment adherence (tolerability) was assessed using conventional (lost to follow-up and attendance) and exploratory (e.g., permanent discontinuation, dose modification, and relative dose intensity) outcomes. RESULTS: The mean total cumulative "planned" and "completed" dose was 200.7 ± 47.6 and 153.8 ± 68.8 MET·h, respectively, equating to a mean relative dose intensity of 77% ± 24%. Two patients (8%) were lost to follow-up, and mean attendance was 79%. A total of 6 (24%) of 25 patients permanently discontinued aerobic training before week 24. Aerobic training was interrupted (missing ≥3 consecutive sessions) or dose reduced in a total of 11 (44%) and 24 (96%) patients, respectively; a total 185 (10%) of 1800 training sessions required dose reduction owing to both health-related (all nonserious) and non-health-related adverse events. Eighteen (72%) patients required at least one session to be terminated early; a total of 59 (3%) sessions required early termination. CONCLUSIONS: Novel methods for the conduct and reporting of exercise treatment adherence and tolerability may provide important information beyond conventional metrics in patients with cancer.
Authors: Jeffrey A Meyerhardt; Denise Heseltine; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Heidi Nelson; Renaud Whittom; Alexander Hantel; Richard L Schilsky; Charles S Fuchs Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: Lee W Jones; Whitney E Hornsby; Stephen J Freedland; Amy Lane; Miranda J West; Judd W Moul; Michael N Ferrandino; Jason D Allen; Aarti A Kenjale; Samantha M Thomas; James E Herndon; Bridget F Koontz; June M Chan; Michel G Khouri; Pamela S Douglas; Neil D Eves Journal: Eur Urol Date: 2013-11-22 Impact factor: 20.096
Authors: Anne McTiernan; Charles Kooperberg; Emily White; Sara Wilcox; Ralph Coates; Lucile L Adams-Campbell; Nancy Woods; Judith Ockene Journal: JAMA Date: 2003-09-10 Impact factor: 56.272
Authors: Lee W Jones; Carolyn J Peddle; Neil D Eves; Mark J Haykowsky; Kerry S Courneya; John R Mackey; Anil A Joy; Vikaash Kumar; Timothy W Winton; Tony Reiman Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: John P Sasso; Neil D Eves; Jesper F Christensen; Graeme J Koelwyn; Jessica Scott; Lee W Jones Journal: J Cachexia Sarcopenia Muscle Date: 2015-05-11 Impact factor: 12.910
Authors: Michael C Hartland; Kade Davison; Maximillian J Nelson; Jonathan D Buckley; Gaynor Parfitt; Joel T Fuller Journal: J Sports Sci Med Date: 2019-08-01 Impact factor: 2.988
Authors: Jessica M Scott; Samantha M Thomas; Jeffrey M Peppercorn; James E Herndon; Pamela S Douglas; Michel G Khouri; Chau T Dang; Anthony F Yu; Diane Catalina; Cristi Ciolino; Catherine Capaci; Meghan G Michalski; Neil D Eves; Lee W Jones Journal: Circulation Date: 2020-02-17 Impact factor: 29.690
Authors: J F Christensen; C Simonsen; A Banck-Petersen; S Thorsen-Streit; A Herrstedt; S S Djurhuus; C Egeland; C E Mortensen; S C Kofoed; T S Kristensen; R S Garbyal; B K Pedersen; L B Svendsen; P Højman; P de Heer Journal: BJS Open Date: 2018-10-24
Authors: Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243
Authors: Ciaran M Fairman; Krissy L Kendall; Robert U Newton; Nicolas H Hart; Dennis R Taaffe; Raphael Chee; Colin I Tang; Daniel A Galvão Journal: BMJ Open Date: 2019-09-20 Impact factor: 2.692
Authors: Gráinne Sheill; Emer Guinan; Linda O'Neill; Charles Normand; Suzanne L Doyle; Sarah Moore; John Newell; Grainne McDermott; Ronan Ryan; John V Reynolds; Juliette Hussey Journal: BMC Cancer Date: 2020-04-15 Impact factor: 4.430
Authors: Asta Bye; Jon A Sandmael; Guro B Stene; Lene Thorsen; Trude R Balstad; Tora S Solheim; Are Hugo Pripp; Line M Oldervoll Journal: Nutrients Date: 2020-10-22 Impact factor: 5.717